A diabetes drug that works on two gut hormones at once (like tirzepatide) lowers blood sugar more than drugs that only target one hormone, reducing HbA1c by over 2 percentage points on average.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Provide a pooled estimate of HbA1c reduction across all trials comparing dual agonists to GLP-1RAs.
A systematic review and meta-analysis of all head-to-head RCTs comparing tirzepatide to semaglutide or other GLP-1RAs in type 2 diabetes, with HbA1c change as the primary outcome, including at least 5 trials and 3,000 participants, using random-effects models.
Establish causal superiority of dual agonists over GLP-1RAs for HbA1c reduction.
A double-blind RCT of 2,000 adults with type 2 diabetes, randomized to tirzepatide 15 mg/week vs semaglutide 2.4 mg/week for 52 weeks, with HbA1c as the primary endpoint, blinded lab assessment, and intention-to-treat analysis.
Evaluate long-term glycemic control and durability of response in routine clinical practice.
A prospective cohort of 8,000 patients with type 2 diabetes initiating tirzepatide or semaglutide, followed for 3 years with HbA1c measured every 6 months via central lab, adjusting for baseline characteristics and concomitant medications.
Estimate the average HbA1c among current users of dual vs mono agonists.
A cross-sectional analysis of 10,000 patients with type 2 diabetes on GLP-1RAs or dual agonists, using electronic health records to extract latest HbA1c, medication type, dose, and duration of use.
Summarize and interpret clinical trial findings for clinicians.
A narrative review by diabetes specialists summarizing HbA1c outcomes from SURPASS and other trials, discussing mechanisms and clinical implications of dual agonism.